Solventum (NYSE:SOLV) beats Q3 2026 sales expectations

Solventum (SOLV) reported Q3 2026 revenue of $1.95 billion, beating estimates by 0.9% but down 7% year-on-year. Adjusted EPS of $1.45 exceeded expectations by 7.9%. The company raised full-year EPS guidance to $7.25. Operating margin fell to 3.5%, while free cash flow improved to $97 million. Organic revenue declined 2.8% year-on-year.

Original reporting
Published Nov 5, 2026, 10:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Solventum (NYSE:SOLV) beats Q3 2026 sales expectations — source image
Decision brief

The 30-second read

$SOLVBullishHigh
01

Why it matters

The earnings beat and guidance raise could prompt short-term buying, but margin compression may limit upside.

02

Market read

Earnings release is a primary corporate event with modest positive market relevance.

03

What to watch

Free cash flow turned positive and guidance raise may be offset by margin weakness.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Solventum reported Q3 2026 results with revenue of $1.95B versus $1.93B estimate and adjusted EPS of $1.45 versus $1.34 estimate.

Company-level read

Ticker impact

$SOLVBullishHigh confidence
Context

Q3 2026 earnings beat revenue and EPS estimates and raised full-year EPS guidance.

Expected impact

likely modest buying pressure as the market prices in the EPS beat and guidance raise.

Evidence & confidence

The earnings release is the first report of the numbers; beat is small and guidance increase modest, so impact is expected to be limited but positive.

Market effects

Provides a modest positive signal for the specialty chemicals sector.

North American markets may see slight uplift in related stocks.

Limited global impact; primarily relevant to US investors.

Counterpoint

The beat is narrow and operating margin collapsed, suggesting deeper operational issues.

Key entities

  • Solventum

    Specialty chemicals producer listed on NYSE.

Related articles

$SOLVMedAI 8/10

SOLV Energy Q3 Revenue Rises 65% to $1.24 Billion; Raises 2026 Guidance

SOLV Energy reported Q3 2026 revenue of $1.24B, up 65% YoY, with net income of $123M. Adjusted EBITDA was $173M, and gross margin was 17.8%. The company raised its 2026 guidance for revenue, adjusted gross profit, and adjusted EBITDA. Growth was driven by new construction and existing infrastructure revenue. SOLV completed its acquisition of ASB Energy Services in October 2026.

$SOLVMed

Solventum (SOLV) stock trades up, here is why

Solventum (SOLV) shares rose 5% after reporting Q3 2026 revenue of $1.95B and EPS of $1.45, and raising full-year EPS guidance to $7.20-$7.30. The company completed ERP cutovers and exited 90% of transition agreements with 3M. Shares cooled to $91.19, up 4.6% from the previous close.

$SOLVMed

Solventum Q3 Earnings Call Highlights

Solventum reported Q3 sales of $1.9B, with mixed performance across segments. Gross margin rose to 57.1%, while operating margin fell to 19.9%. The company raised its full-year earnings outlook to $7.20-$7.30 per share and expects high-end organic sales growth. It also announced plans to separate its Health Information Systems business and renegotiated a raw material supply agreement with 3M.

MedAI 8/10

Solventum Earnings Call Signals Stronger Growth Ahead

Solventum Corporation (SOLV) reported Q3 earnings, highlighting strong execution despite ERP transition challenges. Sales were $1.95B, down 7% YoY, but organic growth was ~4% excluding ERP timing reversals. Gross margin rose to 57.1%, and full-year EPS guidance was raised to $7.20-$7.30. The 3M separation is 90% complete, with margin expansion and cost savings driving growth.